Lerdelimumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458270397

| type = mab

| mab_type = mab

| source = u

| target = TGF beta 2

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Development discontinued

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 285985-06-0

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = GX1FEU3QSM

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.

It was being developed to reduce scarring after glaucoma drainage surgery.{{cite journal | vauthors = | title = Lerdelimumab | journal = Drugs in R&D | volume = 3 | issue = 2 | pages = 106–8 | date = 1 February 2002 | pmid = 12001808 | doi = 10.2165/00126839-200203020-00006 }} Development was stopped in late 2005 after unsuccessful trial results for that condition.{{cite web | title = CAT abandons Trabio after second clinical trial failure |url=https://www.thepharmaletter.com/article/cat-abandons-trabio-after-second-clinical-trial-failure | work = The Pharma Letter | date= 28 March 2005}}